Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Apixaban. |
| Dasatinib | Dasatinib may increase the anticoagulant activities of Relcovaptan. |
| Ursodeoxycholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Hyodeoxycholic Acid. |
| Glucosamine | Glucosamine may increase the antiplatelet activities of Relcovaptan. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Ibritumomab tiuxetan. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Ibrutinib is combined with Relcovaptan. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Obinutuzumab. |
| Pentoxifylline | Pentoxifylline may increase the antiplatelet activities of Relcovaptan. |
| Rivaroxaban | Relcovaptan may increase the anticoagulant activities of Rivaroxaban. |
| Tipranavir | Tipranavir may increase the antiplatelet activities of Relcovaptan. |
| Urokinase | Relcovaptan may increase the anticoagulant activities of Urokinase. |
| Vitamin E | Vitamin E may increase the antiplatelet activities of Relcovaptan. |
| Pentosan polysulfate | The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Relcovaptan. |
| Limaprost | Limaprost may increase the antiplatelet activities of Relcovaptan. |
| Omega-3 fatty acids | Omega-3 fatty acids may increase the antiplatelet activities of Relcovaptan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Relcovaptan is combined with Tositumomab. |
| Lepirudin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Alteplase. |
| Reteplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding can be increased when Relcovaptan is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Relcovaptan is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Streptokinase. |
| Dicoumarol | The risk or severity of bleeding can be increased when Relcovaptan is combined with Dicoumarol. |
| Argatroban | The risk or severity of bleeding can be increased when Relcovaptan is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Ardeparin. |
| Phenindione | The risk or severity of bleeding can be increased when Relcovaptan is combined with Phenindione. |
| Fondaparinux | The risk or severity of bleeding can be increased when Relcovaptan is combined with Fondaparinux. |
| Warfarin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Relcovaptan is combined with Phenprocoumon. |
| Dipyridamole | The risk or severity of bleeding can be increased when Relcovaptan is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Relcovaptan is combined with Epoprostenol. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Relcovaptan is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Relcovaptan is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Coumarin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Relcovaptan is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding can be increased when Relcovaptan is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding can be increased when Relcovaptan is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding can be increased when Relcovaptan is combined with Beraprost. |
| Prasugrel | The risk or severity of bleeding can be increased when Relcovaptan is combined with Prasugrel. |
| Sulodexide | The risk or severity of bleeding can be increased when Relcovaptan is combined with Sulodexide. |
| Semuloparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Semuloparin. |
| Idraparinux | The risk or severity of bleeding can be increased when Relcovaptan is combined with Idraparinux. |
| Cangrelor | The risk or severity of bleeding can be increased when Relcovaptan is combined with Cangrelor. |
| Astaxanthin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Astaxanthin. |
| Otamixaban | The risk or severity of bleeding can be increased when Relcovaptan is combined with Otamixaban. |
| Amediplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Amediplase. |
| Danaparoid | The risk or severity of bleeding can be increased when Relcovaptan is combined with Danaparoid. |
| Dalteparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Dalteparin. |
| Tinzaparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Tinzaparin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Relcovaptan is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Relcovaptan is combined with Ethyl biscoumacetate. |
| Nadroparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Nadroparin. |
| Triflusal | The risk or severity of bleeding can be increased when Relcovaptan is combined with Triflusal. |
| Ticagrelor | The risk or severity of bleeding can be increased when Relcovaptan is combined with Ticagrelor. |
| Ditazole | The risk or severity of bleeding can be increased when Relcovaptan is combined with Ditazole. |
| Vorapaxar | The risk or severity of bleeding can be increased when Relcovaptan is combined with Vorapaxar. |
| Edoxaban | The risk or severity of bleeding can be increased when Relcovaptan is combined with Edoxaban. |
| Sodium citrate | The risk or severity of bleeding can be increased when Relcovaptan is combined with Sodium citrate. |
| Dextran | The risk or severity of bleeding can be increased when Relcovaptan is combined with Dextran. |
| Bemiparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Bemiparin. |
| Parnaparin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Parnaparin. |
| Desirudin | The risk or severity of bleeding can be increased when Relcovaptan is combined with Desirudin. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Relcovaptan is combined with Antithrombin Alfa. |
| Protein C | The risk or severity of bleeding can be increased when Relcovaptan is combined with Protein C. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Relcovaptan is combined with Antithrombin III human. |
| Letaxaban | The risk or severity of bleeding can be increased when Relcovaptan is combined with Letaxaban. |
| Darexaban | The risk or severity of bleeding can be increased when Relcovaptan is combined with Darexaban. |
| Betrixaban | The risk or severity of bleeding can be increased when Relcovaptan is combined with Betrixaban. |
| Nafamostat | The risk or severity of bleeding can be increased when Relcovaptan is combined with Nafamostat. |
| Monteplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Monteplase. |
| Gabexate | The risk or severity of bleeding can be increased when Relcovaptan is combined with Gabexate. |
| Fluindione | The risk or severity of bleeding can be increased when Relcovaptan is combined with Fluindione. |
| Protein S human | The risk or severity of bleeding can be increased when Relcovaptan is combined with Protein S human. |
| Brinase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Brinase. |
| Clorindione | The risk or severity of bleeding can be increased when Relcovaptan is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Relcovaptan is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Relcovaptan is combined with Tioclomarol. |
| Melagatran | The risk or severity of bleeding can be increased when Relcovaptan is combined with Melagatran. |
| Saruplase | The risk or severity of bleeding can be increased when Relcovaptan is combined with Saruplase. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Relcovaptan is combined with (S)-Warfarin. |
| Tocopherylquinone | The risk or severity of bleeding can be increased when Relcovaptan is combined with Tocopherylquinone. |
| Dabigatran | The risk or severity of bleeding can be increased when Relcovaptan is combined with Dabigatran. |